CAS 1018899-04-1 appears in our catalog under these names: Sotagliflozin, Sotagliflozin/ 98%, LX–4211, LX4211, Sotagliflozin 98%. Offered by: TRC, TargetMol, GLPBio, Biosynth, Ambeed. Available pack sizes: 100mg, 1mg, 2mg, 5mg, 10mg, 25mg, 50mg, 500mg.
Sotagliflozin is an S-glycosyl compound that is 1-thio-beta-L-xylopyranose in which the anomeric hydroxy group is replaced by a 4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl group and the thiol is replaced by a methylsulfanediyl group. It is an inhibitor of SGLT1 and SGLT2 that is approved to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure or type 2 diabetes mellitus, chronic kidney disease, and other cardiovascular risk. It has a role as a sodium-glucose transport protein subtype 1 inhibitor, a hypoglycemic agent, an antihypertensive agent, a sodium-glucose transport protein subtype 2 inhibitor and a cardioprotective agent. It is a C-glycosyl compound, a S-glycosyl compound, an aromatic ether and a member of monochlorobenzenes.
Source: ChEBI
| Molecular formula | C21H25ClO5S |
|---|---|
| Molecular weight | 424.9 g/mol |
| IUPAC name | (2S,3R,4R,5S,6R)-2-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-6-methylsulfanyloxane-3,4,5-triol |
| InChIKey | QKDRXGFQVGOQKS-CRSSMBPESA-N |
| SMILES | CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)SC)O)O)O)Cl |
Computed by PubChem (NCBI)